[go: up one dir, main page]

AR060187A1 - Composicion inmunogenica - Google Patents

Composicion inmunogenica

Info

Publication number
AR060187A1
AR060187A1 ARP070101306A ARP070101306A AR060187A1 AR 060187 A1 AR060187 A1 AR 060187A1 AR P070101306 A ARP070101306 A AR P070101306A AR P070101306 A ARP070101306 A AR P070101306A AR 060187 A1 AR060187 A1 AR 060187A1
Authority
AR
Argentina
Prior art keywords
immunogenic composition
type
aureus
pnag
conjugate
Prior art date
Application number
ARP070101306A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0606417A external-priority patent/GB0606417D0/en
Priority claimed from GB0606416A external-priority patent/GB0606416D0/en
Application filed by Glaxosmithkline Biolog Sa, Brigham & Womens Hospital filed Critical Glaxosmithkline Biolog Sa
Publication of AR060187A1 publication Critical patent/AR060187A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones inmunogénicas que comprenden conjugado de PNAG de estafilococos y polisacárido u oligosacárido capsular de tipo 5 y/u 8 de S. aureus. También se describen vacunas, procedimientos de tratamiento que usan y procedimientos para obtener, una composicion inmunogénica que comprende polisacáridos capsulares de tipo 5 y/u 8 y de PNAG. Reivindicacion 47: Conjugado que comprende un polisacárido u oligosacárido de tipo 5 u 8 de S. aureus y una proteína portadora unida mediante un ligador que comprende un enlace covalente de isourea.
ARP070101306A 2006-03-30 2007-03-28 Composicion inmunogenica AR060187A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78724906P 2006-03-30 2006-03-30
US78758706P 2006-03-30 2006-03-30
GB0606417A GB0606417D0 (en) 2006-03-30 2006-03-30 Immunogenic composition
GB0606416A GB0606416D0 (en) 2006-03-30 2006-03-30 Immunogenic composition

Publications (1)

Publication Number Publication Date
AR060187A1 true AR060187A1 (es) 2008-05-28

Family

ID=38180026

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070101306A AR060187A1 (es) 2006-03-30 2007-03-28 Composicion inmunogenica
ARP070101307A AR060188A1 (es) 2006-03-30 2007-03-28 Procedimiento de conjugacion

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070101307A AR060188A1 (es) 2006-03-30 2007-03-28 Procedimiento de conjugacion

Country Status (8)

Country Link
US (2) US8703148B2 (es)
EP (2) EP2026841B1 (es)
JP (2) JP5759671B2 (es)
AR (2) AR060187A1 (es)
CA (2) CA2647450C (es)
ES (2) ES2659925T3 (es)
TW (1) TWI425951B (es)
WO (2) WO2007113224A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101062525B1 (ko) 2002-11-12 2011-09-06 더 브리검 앤드 우먼즈 하스피털, 인크. 포도상구균 감염에 대한 다당류 백신
EP2468769A1 (en) 2004-04-21 2012-06-27 The Brigham and Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
MX2007016237A (es) 2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Composicion inmunogenica.
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
US8146781B2 (en) * 2007-08-09 2012-04-03 Huhtamaki, Inc. Dispenser for viscous condiments
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
AU2008292897B2 (en) 2007-08-31 2015-01-22 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
RS54190B1 (en) 2008-03-03 2015-12-31 Novartis Ag COMPOUNDS AND COMPOSITIONS USED AS TLR FACTORS
WO2010011284A2 (en) * 2008-07-21 2010-01-28 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
KR20170102039A (ko) 2009-04-03 2017-09-06 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
KR20120034612A (ko) * 2009-04-14 2012-04-12 노파르티스 아게 황색 포도상구균에 대한 면역화를 위한 조성물
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
CN102481352A (zh) * 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
EP2445523B1 (en) * 2009-06-22 2019-04-17 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 8 capsular polysaccharide conjugate immunogenic compositions
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
MX338753B (es) * 2009-09-30 2016-04-29 Novartis Ag Conjugacion de polisacaridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
AU2010310919B2 (en) 2009-10-30 2015-05-07 Glaxosmithkline Biologicals S.A. Purification of Staphylococcus aureus type 5 and type 8 capsular saccharides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
WO2011119759A1 (en) 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
EP2560981A2 (en) * 2010-04-23 2013-02-27 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
CA2800774A1 (en) * 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
PL2654784T3 (pl) * 2010-12-22 2017-08-31 Wyeth Llc Stabilne immunogenne kompozycje antygenów staphylococcus aureus
EP2686010A2 (en) * 2011-03-16 2014-01-22 Regents of the University of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
EP3406628A1 (en) * 2011-04-08 2018-11-28 Evaxion Biotech ApS Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
CN103906535B (zh) 2011-08-15 2017-07-14 芝加哥大学 与葡萄球菌蛋白a的抗体相关的组合物和方法
CN104703622B (zh) 2012-04-26 2017-05-24 芝加哥大学 与金黄色葡萄球菌疾病期间抵消凝固酶活性的抗体相关的组合物和方法
ES2806945T3 (es) 2012-04-26 2021-02-19 Univ Chicago Antígenos de coagulasa estafilocócica y métodos para su uso
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
AU2014359277B2 (en) * 2013-12-04 2017-10-26 Glaxosmithkline Biologicals S.A. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli
BE1023004A1 (fr) * 2014-12-10 2016-10-31 Glaxosmithkline Biologicals Sa Procede de traitement
JP7117244B2 (ja) * 2016-02-12 2022-08-12 ザ・ユニバーシティ・オブ・シカゴ 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
JP7132954B2 (ja) 2017-06-10 2022-09-07 インベントプライズ リミテッド ライアビリティ カンパニー 改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3090271A1 (en) 2018-02-12 2019-08-15 Inimmune Corporation Toll-like receptor ligands
US11103567B2 (en) 2018-12-06 2021-08-31 Academia Sinica Glycoconjugate vaccines, preparation method and uses thereof
CA3191005A1 (en) 2020-08-10 2022-02-17 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
US11820989B2 (en) 2020-11-04 2023-11-21 Eligo Bioscience Phage-derived particles for in situ delivery of DNA payload into C. acnes population

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
WO2003053462A2 (en) 2001-12-11 2003-07-03 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
KR101062525B1 (ko) * 2002-11-12 2011-09-06 더 브리검 앤드 우먼즈 하스피털, 인크. 포도상구균 감염에 대한 다당류 백신
CN1787839B (zh) * 2003-03-07 2011-09-28 惠氏控股公司 用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物
JP2007501888A (ja) 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド ポリシアル酸誘導体
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica

Also Published As

Publication number Publication date
ES2659925T3 (es) 2018-03-20
EP2026841B1 (en) 2017-12-27
JP2009531388A (ja) 2009-09-03
AR060188A1 (es) 2008-05-28
JP5491853B2 (ja) 2014-05-14
WO2007113223A2 (en) 2007-10-11
US20100322959A1 (en) 2010-12-23
JP5759671B2 (ja) 2015-08-05
US8703148B2 (en) 2014-04-22
JP2009531389A (ja) 2009-09-03
CA2647450A1 (en) 2007-10-11
EP2019689A2 (en) 2009-02-04
ES2659050T3 (es) 2018-03-13
TWI425951B (zh) 2014-02-11
CA2647455A1 (en) 2007-10-11
WO2007113224A2 (en) 2007-10-11
EP2026841A2 (en) 2009-02-25
TW200815028A (en) 2008-04-01
US8933218B2 (en) 2015-01-13
WO2007113223A3 (en) 2008-08-28
WO2007113224A3 (en) 2008-06-05
EP2019689B1 (en) 2018-01-10
CA2647450C (en) 2014-08-12
US20100303852A1 (en) 2010-12-02
CA2647455C (en) 2014-07-15

Similar Documents

Publication Publication Date Title
AR060187A1 (es) Composicion inmunogenica
PH12021551159A1 (en) Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
EA200801839A1 (ru) Иммуногенная композиция
PH12019502278A1 (en) Conjugation of a cytotoxic drug with bis-linkage
CL2012000744A1 (es) Proceso para preparar un conjugado de polisacáridos capsulares tipo 5 o tipo 8 de s. aureus y una molécula transportadora; conjugado de polisacáridos; y composición inmunogénica que lo comprende.
BRPI0515520A (pt) composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
SI2283857T1 (sl) Sestava cepiva, ki obsega konjugirane nativne kapsularne polisaharide n. meningitidis
GB201101665D0 (en) Immunogenic compositions
MY167579A (en) Glycoconjugation processes and compositions
NZ588884A (en) Cross-linkers and their uses
AR080122A1 (es) Composicion de vacuna conjugada de polisacarido-proteina neumococica 15-valente
TNSN08463A1 (en) Leptomycin derivatives
BRPI0915517B8 (pt) método para a produção de um conjugado de vi, conjugado, e, composição farmacêutica
AR060182A1 (es) Polisacaridos capsulares tipo 5 y tipo 8 de cepas s. aureus de sobreproduccion
UA97359C2 (en) Immunogenic composition
BRPI0516770A (pt) vacina e conjugados de proteìna - derivados de polissacarìdeo de meningocócico multivalente
BR112017028395A2 (pt) ?polissacarídeo capsular bacteriano, conjugado, e, composição farmacêutica?
BRPI0515125A (pt) conjugados de polissacarìdeo derivatizado-proteìna multivalentes, meningocócicos e vacina
BRPI0516372A (pt) conjugados de polissacarìdeo-proteìna derivatizados meningocócicos multivalentes e vacina
TW200806314A (en) Immunogenic composition
MX349930B (es) Composiciones inmunogenas.

Legal Events

Date Code Title Description
FG Grant, registration